Patient Care Costs in Cancer Clinical Trials

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

Rep. Pryce is also cochair of the House Cancer Working Group. In March, she introduced the Access to Cancer Clinical Trials Act (H.R. 967), which would require health insurers to pay for the routine costs incurred by patients in

Rep. Pryce is also cochair of the House Cancer Working Group. InMarch, she introduced the Access to Cancer Clinical Trials Act(H.R. 967), which would require health insurers to pay for the routine costsincurred by patients in cancer clinical trials. This would be a further step infederal policy beyond the Clinton administration’s national coverage decisionthat went into effect in September 2000. The Pryce bill calls for coverage ofall participants in cancer clinical trials, regardless of age, including thoseconducted by nonfederal research entities—a category of trials not included inthe Clinton policy.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content